GlobeNewswire Inc.··NovartisNovartis Fabhalta Shows 49% Slowing of Kidney Decline in Landmark IgAN Study
Novartis' Fabhalta slowed kidney function decline by 49.3% in Phase III trial, with FDA priority review granted for IgA nephropathy treatment.
NVSFDA approvalkidney disease